Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
TV & Film
Technology
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/03/85/bf/0385bf00-4f5f-1d37-7e70-cdfd5676802b/mza_1155440752639581066.jpeg/600x600bb.jpg
"Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD
Christina Farr, Luba Greenwood, Ash Zenooz
39 episodes
4 months ago
If you’re obsessed with health-tech and life sciences, this is the podcast for you. Second Opinion doesn't hold back. Join Luba Greenwood, Christina Farr, and Ash Zenooz as they bring influential entrepreneurs, experts and investors into the ring for candid conversations at the frontlines of healthcare and digital health every week. Healthcare, health-tech and life sciences in particular, is hard to navigate even for the most seasoned professionals. Unpacking the latest technological, medical, and scientific advances, regulatory hurdles, global economic shifts, and industry and investment trends, requires a powerful combination of hosts like us. We aim to sift through the noise and help you navigate what’s really going on in healthcare and how to spot the next win. This season, we’re tackling meaty topics like biosecurity, the latest in telemedicine, why patient acquisition is so hard, and the pros and cons of VC versus private equity in funding startups in the healthtech space. Christina Farr is a former investigative journalist for CNBC — during her tenure as a reporter, she broke some big health-tech stories ranging from Amazon’s first moves into the sector to Apple’s secretive acquisitions. Now Christina is the author at Second Opinion, a newsletter with +20K subscribers. Joining Christina are co-hosts Luba Greenwood, JD — former CEO of Kojin Therapeutics and managing partner at Dana-Farber Cancer Institute — and Ash Zenooz, MD — former CEO of Commure and partner at Luxeda Holdings.  Second Opinion is is a part of the Turpentine podcast network. Learn more: turpentine.co
Show more...
Technology
Business,
Investing,
Health & Fitness
RSS
All content for "Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD is the property of Christina Farr, Luba Greenwood, Ash Zenooz and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
If you’re obsessed with health-tech and life sciences, this is the podcast for you. Second Opinion doesn't hold back. Join Luba Greenwood, Christina Farr, and Ash Zenooz as they bring influential entrepreneurs, experts and investors into the ring for candid conversations at the frontlines of healthcare and digital health every week. Healthcare, health-tech and life sciences in particular, is hard to navigate even for the most seasoned professionals. Unpacking the latest technological, medical, and scientific advances, regulatory hurdles, global economic shifts, and industry and investment trends, requires a powerful combination of hosts like us. We aim to sift through the noise and help you navigate what’s really going on in healthcare and how to spot the next win. This season, we’re tackling meaty topics like biosecurity, the latest in telemedicine, why patient acquisition is so hard, and the pros and cons of VC versus private equity in funding startups in the healthtech space. Christina Farr is a former investigative journalist for CNBC — during her tenure as a reporter, she broke some big health-tech stories ranging from Amazon’s first moves into the sector to Apple’s secretive acquisitions. Now Christina is the author at Second Opinion, a newsletter with +20K subscribers. Joining Christina are co-hosts Luba Greenwood, JD — former CEO of Kojin Therapeutics and managing partner at Dana-Farber Cancer Institute — and Ash Zenooz, MD — former CEO of Commure and partner at Luxeda Holdings.  Second Opinion is is a part of the Turpentine podcast network. Learn more: turpentine.co
Show more...
Technology
Business,
Investing,
Health & Fitness
https://megaphone.imgix.net/podcasts/8fa42950-5ca4-11f0-92a4-2f4121f9327d/image/38b573bb5031f5655dfe4406aff77b60.png?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress
Lantern's Dickon Waterfield on rising healthcare costs and how Medicaid cuts will impact businesses
"Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD
49 minutes
4 months ago
Lantern's Dickon Waterfield on rising healthcare costs and how Medicaid cuts will impact businesses
In this episode of the Second Opinion, Christina Farr interviews Dickon Waterfield, president of Lantern to discuss the intricacies of U.S. healthcare costs, particularly the disparity between Medicare and commercial prices. They cover the unsustainable burden on employers to provide healthcare, the evolving nature of digital health solutions, and the market's reaction to recent IPOs in the sector. —📰 Be notified early when Turpentine drops new publication: https://www.turpentine.co/exclusiveaccess  —LINKS: Lantern: https://lanterncare.com/  Christina Farr's Second Opinion Newsletter: https://secondopinion.media/  —SPONSOR: 👩‍⚕️ Hot flashes, insomnia, brain fog? You don't have to accept these as just another part of aging. Midi Health is the virtual care clinic for women navigating midlife hormonal transition, offering FDA-approved medications, supplements and lifestyle coaching - all covered by insurance. Visit https://joinmidi.com to book your virtual visit today.—FOLLOW:https://www.linkedin.com/in/dickonwaterfield https://www.linkedin.com/in/christinafarr/—HIGHLIGHTS FROM THE EPISODE: • The company was previously under the radar despite its size because it lacked traditional digital health investors and operated in the emerging "sensitive excellence" space • Lantern works by securing lower rates from select providers in exchange for steering patient volume to them, rather than contracting with all providers like traditional insurers • Commercial insurance pays dramatically more than Medicare for the same procedures - for example, a total knee replacement costs around $45,000 commercially versus $17,000 for Medicare • About 90% of surgical costs go to the facility, with only 10% split between surgeon and anesthesia fees • The company built scale over 14 years by starting with local networks and school districts before expanding to national employers • They typically contract with only one or two providers per market, offering them incremental volume and market share gains • By waiving patient cost-sharing (like $5,000 out-of-pocket maximums), they incentivize patients to travel to preferred providers • Proposed Medicaid cuts could affect 10% of Medicaid recipients, forcing more healthcare costs onto employers • When Medicaid funding decreases, hospitals typically increase commercial rates to compensate for uninsured patients • Employers are increasingly frustrated with being responsible for 60-70% of Americans' healthcare coverage • The current system originated post-WWII as a talent competition tool and became normalized as part of total compensation packages • Only a major economic downturn with high unemployment could potentially break this cycle, as tight labor markets force employers to maintain competitive benefits • Employers will likely narrow their coverage, offering less rich benefits and more selective networks and formularies • Cell and gene therapies costing $1-5 million per treatment pose existential threats to employer-sponsored health plans • There's a reckoning coming for point solutions that don't deliver measurable ROI, with increased scrutiny on clinical evidence and cost reduction • Digital health companies are held to higher standards than pharmaceuticals, which don't face the same outcome-based payment requirements • Forward-thinking employers are moving beyond simple cost savings to evaluate programs on multiple parameters including talent retention and clinical outcomes • A new generation of digital health companies is becoming in-network providers rather than selling directly to employers • This approach eliminates long sales cycles and complex billing arrangements that characterized earlier digital health companies • Successful healthcare sales requires understanding buyers' needs and solving their problems rather than just selling solutions • Founder-led sales remains crucial in early stages because founders can listen more acutely to feedback and pivot quickly
"Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD
If you’re obsessed with health-tech and life sciences, this is the podcast for you. Second Opinion doesn't hold back. Join Luba Greenwood, Christina Farr, and Ash Zenooz as they bring influential entrepreneurs, experts and investors into the ring for candid conversations at the frontlines of healthcare and digital health every week. Healthcare, health-tech and life sciences in particular, is hard to navigate even for the most seasoned professionals. Unpacking the latest technological, medical, and scientific advances, regulatory hurdles, global economic shifts, and industry and investment trends, requires a powerful combination of hosts like us. We aim to sift through the noise and help you navigate what’s really going on in healthcare and how to spot the next win. This season, we’re tackling meaty topics like biosecurity, the latest in telemedicine, why patient acquisition is so hard, and the pros and cons of VC versus private equity in funding startups in the healthtech space. Christina Farr is a former investigative journalist for CNBC — during her tenure as a reporter, she broke some big health-tech stories ranging from Amazon’s first moves into the sector to Apple’s secretive acquisitions. Now Christina is the author at Second Opinion, a newsletter with +20K subscribers. Joining Christina are co-hosts Luba Greenwood, JD — former CEO of Kojin Therapeutics and managing partner at Dana-Farber Cancer Institute — and Ash Zenooz, MD — former CEO of Commure and partner at Luxeda Holdings.  Second Opinion is is a part of the Turpentine podcast network. Learn more: turpentine.co